Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus lasofoxifene versus abemaciclib plus fulvestrant in ESR1-mutant ER-positive/HER2-negative advanced breast cancer
CTR20242519Phase 3Active
- Sponsor
- 不适用/ 上海复宏汉霖生物技术股份有限公司/ Catalent Greenville, Inc.
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of abemaciclib, lasofoxifene, fulvestrant in breast cancer, sponsored by 不适用/ 上海复宏汉霖生物技术股份有限公司/ Catalent Greenville, Inc.. Started Dec 2024; status: active.
02
Drugs
abemacicliblasofoxifenefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20242519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242519.